Galectin Therapeutics Inc (NASDAQ:GALT)
| 4.40 Data as of May 17 |  +0.18 / +4.27%Today’s Change | 1.60 Today|||52-Week Range 5.22 | +114.63% Year-to-Date |
Latest GALT News | Press Releases
No recent news for Galectin Therapeutics Inc.
Today’s Trading
| Previous close | 4.22 |
| Today’s open | 4.19 |
| Day’s range | 4.10 - 4.45 |
| Volume | 28,093 |
| Average volume (3 months) | 92,721 |
| Market cap | $71.5M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/17/2013
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +4.17% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 132.57 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TTHITransition Therapeut... | +0.02 | +0.69% |
| LPDXLipoScience Inc | +0.20 | +3.58% |
| INISInternational Isotop... | +0.01 | +7.14% |
| --MetaStat Inc | 0.00 | 0.00% |
Data as of 4:00pm ET, 05/17/2013
Financials
| Last reporting date | May 15, 2013 |
| EPS forecast (this quarter) | -$0.18 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$9.9M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
Executive Chairman James C. Czirr |
President, CEO, Director & Chief Medical Officer Peter G. Traber, MD |
Corporate headquarters Newton, Massachusetts |
Forecasts
